PMID- 18754880
OWN - NLM
STAT- MEDLINE
DCOM- 20081006
LR  - 20161124
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 99
IP  - 8
DP  - 2008 Aug
TI  - Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability 
      to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ 
      glioma patients.
PG  - 1656-62
LID - 10.1111/j.1349-7006.2008.00866.x [doi]
AB  - We recently cloned a variant form of erythropoietin-producing hepatocyte (Eph)B6, 
      a member of the Eph receptor tyrosine kinase family. In the present study, we 
      examined the expression of the EphB6 variant (EphB6v) in a panel of brain tumor 
      cell lines and glioblastoma tissues and we found that EphB6v was preferentially 
      expressed in malignant brain tumors, such as glioblastomas and anaplastic 
      astrocytomas. The EphB6v has a unique 54 amino acid sequence at the C-terminal 
      that is not found in normal EphB6. Therefore, we attempted to identify antigenic 
      peptides unique to EphB6v for immunotherapy. The two EphB6v-derived peptides 
      exhibited the ability to bind to human leukocyte antigen (HLA)-A0201 molecules, 
      and each of them was able to induce cytotoxic T lymphocytes in vitro in the 
      peripheral blood mononuclear cells of HLA-A2(+) glioma patients. The cytotoxicity 
      was mediated by peptide-specific CD8(+) T cells in an HLA-A2-restricted manner. 
      The expression of EphB6v was also observed in different types of cancer (e.g. 
      lung, colon, stomach, liver and pancreatic) cells. Taken together, the two 
      peptides derived from EphB6v might be appropriate targets for peptide-based 
      specific immunotherapy for HLA-A2(+) patients with various cancers.
FAU - Jin, Mingyue
AU  - Jin M
AD  - Cancer Vaccine Development Division, Kurume University Research Center for 
      Innovative Cancer Therapy, Kurume, Fukuoka 830-0011, Japan.
FAU - Komohara, Yoshihiro
AU  - Komohara Y
FAU - Shichijo, Shigeki
AU  - Shichijo S
FAU - Yamanaka, Ryuya
AU  - Yamanaka R
FAU - Nikawa, Junichi
AU  - Nikawa J
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Yamada, Akira
AU  - Yamada A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A*02:01 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - EC 2.7.10.1 (EPHB6 protein, human)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptors, Eph Family)
SB  - IM
MH  - Astrocytoma/metabolism
MH  - Brain Neoplasms/metabolism
MH  - Case-Control Studies
MH  - Cell Line, Tumor
MH  - Gene Expression
MH  - *Gene Expression Regulation
MH  - Glioblastoma/metabolism
MH  - HLA-A Antigens
MH  - HLA-A2 Antigen
MH  - Hepatocytes
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Receptor Protein-Tyrosine Kinases/*metabolism
MH  - Receptors, Eph Family
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 2008/08/30 09:00
MHDA- 2008/10/07 09:00
CRDT- 2008/08/30 09:00
PHST- 2008/08/30 09:00 [pubmed]
PHST- 2008/10/07 09:00 [medline]
PHST- 2008/08/30 09:00 [entrez]
AID - CAS866 [pii]
AID - 10.1111/j.1349-7006.2008.00866.x [doi]
PST - ppublish
SO  - Cancer Sci. 2008 Aug;99(8):1656-62. doi: 10.1111/j.1349-7006.2008.00866.x.